Urotensin-II-Targeted Liposomes as a New Drug Delivery System towards Prostate and Colon Cancer Cells

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="6"><hr/></td></tr><tr class="thead"><td class="align_left">Formulation</td><td class="align_center">Encapsulation efficiency doxo (%)</td><td class="align_center">Diameter (nm ± SD)</td><td class="align_center">PI ± SD</td><td class="align_center"><i>ζ</i> (mV ± SD)</td><td class="align_center">UT-II on the surface of liposomes (%)</td></tr><tr><td class="thead-hr" colspan="6"><hr/></td></tr><tr><td class="align_left">Lipo-doxo</td><td class="align_center">90</td><td class="align_center">148.9 ± 8.27</td><td class="align_center">0.102 ± 0.06</td><td class="align_center">−18.76 ± 3.74</td><td class="align_center">—</td></tr><tr><td class="align_left">LipoUT-doxo</td><td class="align_center">96</td><td class="align_center">190.9 ± 17.42</td><td class="align_center">0.247 ± 0.11</td><td class="align_center">−28.89 ± 2.15</td><td class="align_center">60%</td></tr><tr class="table-tr"><td colspan="6"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Mean diameter, PI, and zeta potential (<i>ζ</i>) of liposomes encapsulating doxo conjugated (LipoUT-doxo) and unconjugated (Lipo-doxo).</div>

Journal of Oncology

tab2

Table 2

Table 2: Urotensin-II-Targeted Liposomes as a New Drug Delivery System towards Prostate and Colon Cancer Cells 